Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Cosentyx\u00ae Gains EU Label Update for First-Of-Its-Kind Maximise Data in Axial Manifestations of Psoriatic Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Novartis Pharmaceuticals Corporation"},{"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis PREVENT Data Show Cosentyx\u00ae Helps Patients Realize Early and Lasting Relief in Axial Spondyloarthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Novartis Pharmaceuticals Corporation"},{"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Presents Positive Phase III Results for Cosentyx\u00ae in Children with Active Enthesitis-Related Arthritis (ERA) And Juvenile Psoriatic Arthritis (JPsA) at ACR 2021","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Novartis Pharmaceuticals Corporation"},{"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Cosentyx\u00ae Receives FDA Approval for The Treatment of Children and Adolescents with Enthesitis-Related Arthritis and Psoriatic Arthritis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Novartis Pharmaceuticals Corporation"},{"company":"Vifor Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VFMCRP Receives EU Approval for Tavneos\u00ae for the Treatment of ANCA-Associated Vasculitis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"January 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Vifor Pharma"},{"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Reports Positive Results from Cosentyx Trial","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"May 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Novartis Pharmaceuticals Corporation"},{"company":"Novartis Pharmaceuticals Corporation","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Receives European Commission Approval for Jakavi\u00ae to Be the First Post-steroid Treatment for Acute and Chronic Graft-versus-host Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Novartis Pharmaceuticals Corporation"},{"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cosentyx\u00ae (Secukinumab) Receives Expanded Approvals in EU for Use in Childhood Arthritic Conditions","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Novartis Pharmaceuticals Corporation"},{"company":"Vifor Pharma","sponsor":"ChemoCentryx","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tavneos\u00ae (avacopan) Recommended by England\u2019s NICE for the Treatment of AAV (GPA\/MPA)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Vifor Pharma"},{"company":"Neovii","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neovii and Fosun Pharma Enter Into an Exclusive Agreement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Neovii"}]

Neovii

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Neovii and Fosun Pharma Enter Into an Exclusive Agreement

Details:

Under the Agreement Neovii is entitled to receive upfront, regulatory and commercial sales milestones as well as proceeds from supplying Grafalon® (Rabbit Anti-human T-lymphocyte Globulin) to Fosun Pharma Industry.

Lead Product(s): Rabbit Anti-human T-lymphocyte Globulin

Therapeutic Area: Immunology Product Name: Grafalon

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Fosun Pharmaceutical

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement September 07, 2022

ASK
US

Upload
your Pipeline Activity

Vifor Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Tavneos® (avacopan) Recommended by England’s NICE for the Treatment of AAV (GPA/MPA)

Details:

Tavneos® (avacopan) is an orally administered small molecule that is a selective inhibitor of the complement C5a receptor C5aR1,reduces the ability of those cells to do damage in response to C5a activation.

Lead Product(s): Avacopan,Rituximab,Cyclophosphamide

Therapeutic Area: Immunology Product Name: Tavneos

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: ChemoCentryx

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 18, 2022

ASK
US

Upload
your Pipeline Activity

Novartis Pharmaceuticals Corporation

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Cosentyx® (Secukinumab) Receives Expanded Approvals in EU for Use in Childhood Arthritic Conditions

Details:

Approvals based on data from the JUNIPERA trial, showing that Cosentyx® (secukinumab) reduced the risk of flare and disease activity compared to placebo over 2 years in pediatric patients1 with enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA).

Lead Product(s): Secukinumab

Therapeutic Area: Immunology Product Name: Cosentyx

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 27, 2022

ASK
US

Upload
your Pipeline Activity

Novartis Pharmaceuticals Corporation

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Novartis Receives European Commission Approval for Jakavi® to Be the First Post-steroid Treatment for Acute and Chronic Graft-versus-host Disease

Details:

In clinical trials, Jakavi (ruxolitinib) demonstrated superiority versus best available therapy in patients with steroid-refractory/dependent acute and chronic GvHD, with overall response rates of 62% vs. 39%, and 50% vs. 26% respectively.

Lead Product(s): Ruxolitinib Phosphate

Therapeutic Area: Immunology Product Name: Jakavi

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Incyte Corporation

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 05, 2022

ASK
US

Upload
your Pipeline Activity

Vifor Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

VFMCRP Receives EU Approval for Tavneos® for the Treatment of ANCA-Associated Vasculitis

Details:

EU approval for Tavneos (avacopan) is based on culminating in the results from the pivotal phase-III trial ADVOCATE in 331 patients with ANCA-associated vasculitis also met its primary endpoints of disease remission at week 26 and sustained remission at week 52.

Lead Product(s): Avacopan,Rituximab

Therapeutic Area: Immunology Product Name: Tavneos

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 19, 2022

ASK
US

Upload
your Pipeline Activity

Novartis Pharmaceuticals Corporation

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Novartis Cosentyx® Receives FDA Approval for The Treatment of Children and Adolescents with Enthesitis-Related Arthritis and Psoriatic Arthritis

Details:

New approvals are based on JUNIPERA trial data showing Cosentyx (secukinumab) demonstrated reduced flare risk versus placebo and improvement in disease activity observed over two years across both enthesitis-related arthritis and psoriatic arthritis in pediatric patients.

Lead Product(s): Secukinumab

Therapeutic Area: Immunology Product Name: Cosentyx

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 23, 2021

ASK
US

Upload
your Pipeline Activity

Novartis Pharmaceuticals Corporation

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Novartis Presents Positive Phase III Results for Cosentyx® in Children with Active Enthesitis-Related Arthritis (ERA) And Juvenile Psoriatic Arthritis (JPsA) at ACR 2021

Details:

Two-year results from JUNIPERA demonstrated that patients treated with Cosentyx had a significantly longer time to flare, showing a 72% reduction in the risk of flare versus placebo, in children and adolescents ages two to 17 years old.

Lead Product(s): Secukinumab

Therapeutic Area: Immunology Product Name: Cosentyx

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 08, 2021

ASK
US

Upload
your Pipeline Activity

Novartis Pharmaceuticals Corporation

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Novartis PREVENT Data Show Cosentyx® Helps Patients Realize Early and Lasting Relief in Axial Spondyloarthritis

Details:

Phase III PREVENT data show Cosentyx® 150 mg provided significant and sustained improvement in signs and symptoms of non-radiographic axial spondyloarthritis (nr-axSpA) up to Week 52.

Lead Product(s): Secukinumab

Therapeutic Area: Immunology Product Name: Cosentyx

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 02, 2021

ASK
US

Upload
your Pipeline Activity

Novartis Pharmaceuticals Corporation

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Novartis Cosentyx® Gains EU Label Update for First-Of-Its-Kind Maximise Data in Axial Manifestations of Psoriatic Arthritis

Details:

Cosentyx® (secukinumab) is the first biologic with proven efficacy in all 6 key manifestations of psoriatic arthritis (PsA), and the only biologic with fast and lasting relief of axial manifestations of PsA in a dedicated trial.

Lead Product(s): Secukinumab

Therapeutic Area: Immunology Product Name: Cosentyx

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 26, 2021

ASK
US

Upload
your Pipeline Activity

Novartis Pharmaceuticals Corporation

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Novartis Reports Positive Results from Cosentyx Trial

Details:

12-week results from the first-of-its-kind Phase IIIb ULTIMATE randomized controlled trial demonstrated significant treatment response of Cosentyx® (secukinumab) on synovitis (joint lining inflammation) in psoriatic arthritis (PsA) versus placebo.

Lead Product(s): Secukinumab

Therapeutic Area: Immunology Product Name: Cosentyx

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 11, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY